Clinical trial
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
NCT00346385 · ImmunoGen, Inc., Industry · Completed
Key facts
| NCT number | NCT00346385 |
|---|---|
| Title | BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors |
| Official title | A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901 |
| Lead sponsor | ImmunoGen, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Merkel Cell Carcinoma, SCLC |
| Intervention type | Drug |
| Interventions | BB-10901 |
| Enrollment | 97 |
| Start date | Mar 1, 2002 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Jun 29, 2006 |
| Last update posted | Mar 26, 2015 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: